What is Chemed's revenue?

Chemed (CHE) generated $2.5B in revenue over the trailing twelve months, up 2.1% year over year.

Is Chemed profitable?

Chemed reported $259.8M in net income over the trailing twelve months, a 10.2% net margin.

What are Chemed's profit margins?

Gross margin is 32.4% and operating margin is 12.9%, with a 10.2% net margin.

What is Chemed's earnings per share?

Chemed's diluted EPS over the trailing twelve months is $18.32.

Where does Chemed's income statement data come from?

Every line is extracted from Chemed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Chemed CHE Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$2.53B+4.1%	$2.43B+7.4%	$2.26B+6.1%	$2.13B-0.2%
Rental income	$123K-60.5%	$311K+238%	$92K-48.9%	$180K-1.1%
Total cost of revenue	$1.71B+8.2%	$1.58B+7.6%	$1.47B+7.0%	$1.37B0.0%
Gross profit	$823.18M-3.6%	$854.35M+7.0%	$798.82M+4.4%	$765.09M-0.6%
Gross margin	32.5%-2.6pp	35.1%-0.1pp	35.3%-0.6pp	35.8%-0.1pp
Selling, general and administrative	$417.19M-1.7%	$424.36M+7.4%	$395.12M+10.1%	$358.73M-2.2%
Compensation and benefits	$170.06M+1.4%	$167.79M+2.6%	$163.57M+5.3%	$155.37M—
Occupancy and equipment	$68.63M+6.6%	$64.36M+7.6%	$59.81M-2.6%	$61.39M-0.2%
Advertising	$77.14M+5.5%	$73.15M+8.0%	$67.71M+9.9%	$61.63M-0.8%
Depreciation and amortization	$64.84M+2.8%	$63.05M+3.6%	$60.87M+2.9%	$59.17M+0.2%
Other operating expenses	$2.19B+6.1%	$2.06B+7.3%	$1.92B+7.4%	$1.79B+181,606%
Total operating expenses	$2.19B+6.1%	$2.06B+7.3%	$1.92B+7.4%	$1.79B—
Total costs & expenses	$2.19B+6.1%	$2.06B+7.3%	$1.92B+7.4%	$1.79B-0.3%
Operating income	$338.25M-7.7%	$366.49M+7.6%	$340.57M-0.9%	$343.5M+0.1%
Operating margin	13.4%-1.7pp	15.1%0.0pp	15%-1.0pp	16.1%+0.1pp
Interest expense	$1.75M-1.7%	$1.78M-42.7%	$3.11M-32.2%	$4.58M+145%
Interest income	$8.75M-40.1%	$14.61M+133%	$6.27M+1,661%	$356K-5.3%
Other income (expense), net	$19.28M-44.5%	$34.75M+169%	$12.91M—	——
Income before income taxes	60,611,100,000%-7,269,600,000%	67,880,700,000%+9,366,600,000%	58,514,100,000%+818,300,000%	57,695,800,000%-2,754,300,000%
Income tax expense	$90.54M-7.1%	$97.47M+25.2%	$77.86M-2.7%	$80.06M-2.1%
Net income	$265.24M-12.2%	$302M+10.8%	$272.51M+9.2%	$249.62M-7.0%
Net margin	10.5%-1.9pp	12.4%+0.4pp	12%+0.3pp	11.7%-0.9pp
Diluted earnings per share	$18.34-7.8%	$19.90+11.0%	$17.93+8.5%	$16.52-2.0%
Basic earnings per share	$18.42-8.4%	$20.10+11.0%	$18.10+8.3%	$16.72-2.5%
Weighted-average shares, diluted	58.3M-4.3%	60.9M+0.4%	60.7M+0.5%	60.4M-5.8%
Weighted-average shares, basic	58M-3.8%	60.3M+0.2%	60.1M+0.7%	59.7M-5.3%
Adjustment For Amortization	$10.28M+1.0%	$10.19M+1.2%	$10.06M-0.1%	$10.07M+0.3%
Advertising costs	$77.14M+5.5%	$73.15M+8.0%	$67.71M+9.9%	$61.63M-0.8%
Advertising Including Advertising Expense In Cost Of Goods Sold	$83.1M+5.5%	$78.8M+9.1%	$72.2M+5.2%	$68.6M—
Pre-tax stock-based compensation cost	$38.68M-25.8%	$52.11M+27.7%	$40.79M+21.4%	$33.61M+7.0%
Amortization Of Financing Costs	$321K0.0%	$321K-44.7%	$580K+69.6%	$342K+11.8%
Amortization of capitalized software and acquired intangible assets	$10.3M+1.0%	$10.2M+1.0%	$10.1M0.0%	$10.1M+1.0%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	$2,235,000.00+79.4%	$1,246,000.00+0.6%	$1,238,000.00-40.9%	$2,095,000.00+82.5%
Software amortization expense	$4.3M0.0%	$4.3M-4.4%	$4.5M-18.2%	$5.5M-5.2%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect	——	——	——	——
Charity Care Direct And Indirect Cost Basis Amount	——	——	——	——
Cash dividend per common share (in dollars per share)	$2.20+22.2%	$1.80+15.4%	$1.56+5.4%	$1.48+5.7%
Dividends declared (in dollars per share)	——	——	——	——
Other occupancy	$286.66M+8.1%	$265.29M-0.2%	$265.92M+3.3%	$257.44M—
Federal	$83.41M-2.8%	$85.8M+13.9%	$75.33M+42.4%	$52.91M-18.1%
Foreign	$406K-19.0%	$501K-12.0%	$569K+12.7%	$505K-1.2%
Current State And Local Tax Expense Benefit	$12.67M-17.2%	$15.3M+53.3%	$9.98M-15.5%	$11.81M-17.0%
Deferred Federal State And Local Income Tax Expense Benefit	-$5.94M-43.5%	-$4.14M+48.4%	-$8.03M-154%	$14.82M+529%
Deferred Foreign Income Tax Expense Benefit	-$3K-250%	$2K0.0%	$2K-66.7%	$6K-85.7%
Deferred taxes	——	——	——	$14.83M+518%
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	$32.38M-17.3%	$39.13M+47.8%	$26.48M+130%	$11.53M-59.6%
Depreciation	$54.56M+3.2%	$52.86M+4.1%	$50.8M+3.5%	$49.1M+0.2%
Dividends, Common Stock, Cash	$31.7M+17.0%	$27.09M+15.3%	$23.5M+6.7%	$22.02M0.0%
Income taxes at U.S. statutory rate of 21%	——	——	——	——
Effective Income Tax Rate Reconciliation Limitation On Executive Compensation	$4.43M-26.4%	$6.01M+14.1%	$5.27M—	——
Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent	——	——	——	——
Other	$0+33.3%	$00.0%	$0—	——
Excess tax benefits associated with employee equity plans (in percent)	——	——	——	——
Excess tax benefits associated with employee equity plans	——	-13,100,000%+77,400,000%	-90,500,000%-1,115,500,000%	1,025,000,000%-491,800,000%
Compensation and employee benefits	$38.3M-26.6%	$52.19M+24.9%	$41.77M+22.7%	$34.06M—
Excise Tax On Share Repurchase	——	-$2.25M—	——	——
Goodwill Additions	——	$81.87M—	——	$2.79M—
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	——	——	——
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	$1.47M+3.2%	$1.43M+7.1%	$1.33M—	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$480K+139%	-$1.23M-317%	-$295K—	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	$8.75M-25.9%	$11.81M+412%	$2.31M-77.4%	$10.21M+1.8%
Income taxes paid	$102.7M+4.0%	$98.73M+33.6%	$73.88M+12.1%	$65.89M-33.7%
Accounts payable	——	——	——	——
Increase (Decrease) in Accounts Receivable	——	-$10.68M-126%	$41.49M+1,619%	$2.41M-71.4%
Increase Decrease In Accrued Income Taxes Payable	——	$2.18M—	——	——
Increase (Decrease) in Inventories	-$650K+83.1%	-$3.84M—	——	——
Increase Decrease In Lease Assets And Liabilities	$806K+19.6%	$674K—	——	——
Increase (Decrease) in Other Operating Assets	——	$25.59M+157%	$9.95M-78.3%	$45.78M—
Other liabilities	$10.42M-54.2%	$22.75M+77.7%	$12.8M—	——
Increase Decrease In Outstanding Checks Financing Activities	$11.1M—	——	$15.75M+233%	-$11.88M—
Increase (Decrease) in Prepaid Expense	——	——	——	——
Diluted effect of share purchase plans related to Class A ordinary shares (in shares)	——	——	$140K+18.6%	$118K-9.9%
Add - Incremental shares under stock-based compensation plans (in shares)	——	——	$296K—	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	$1.35M+15.8%	$1.16M-56.1%	$2.65M-28.6%	$3.71M+164%
Net interest and investment income (loss)	$8.75M-40.1%	$14.61M+133%	$6.27M+1,661%	$356K-5.3%
Lease Cost	$68.5M+7.0%	$64.05M+7.3%	$59.72M-2.4%	$61.21M-0.2%
Lessee Operating Lease Lease Signed But Not Yet Commenced Payments	——	——	——	——
Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease	$81K+101%	-$10.37M-51.2%	-$6.86M-18.5%	-$5.79M+8.6%
Loss Contingency Damages Sought Value	——	——	——	——
Market Value Gains On Assets Held In Deferred Compensation Trust	$10.55M-47.6%	$20.14M+215%	$6.4M—	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$432.77M-20.5%	-$359.19M-350%	-$79.83M+61.9%	-$209.25M+45.0%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$59.34M+58.8%	-$143.91M-137%	-$60.64M-2.1%	-$59.4M-2.8%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$388.27M-7.0%	$417.5M+26.4%	$330.3M+6.6%	$309.89M+0.4%
Number Of Hospice Programs Exceeding Payment Limits On Inpatient Services	——	——	——	——
Number of reportable segments	2—	——	——	——
Number Of Wholly Owned Subsidiaries	20.0%	20.0%	20.0%	20.0%
Operating Lease Payments	$55.6M+7.4%	$51.76M+4.0%	$49.78M+0.4%	$49.57M-2.8%
Operating Lease Payments Include To Extended Lease Terms	$8.4M—	——	——	——
Other income, net (Note 6)	-$13K—	——	$233K-38.8%	$381K-17.7%
All other operating activities	——	$1.77M+112%	$836K—	——
Other income, net	-$2.91M-552%	-$446K+80.3%	-$2.26M+38.7%	-$3.69M-274%
Patient Care Expense	$166.68M+12.5%	$148.17M+17.4%	$126.26M+8.5%	$116.34M—
Payment for (Proceeds from) Other Investing Activity	$888K+201%	$295K-32.0%	$434K-50.7%	$880K—
Payments for Repurchase of Common Stock	$431.5M+19.4%	$361.39M—	——	$114.52M-80.1%
Payments of Ordinary Dividends, Common Stock	$31.7M+17.0%	$27.09M+15.3%	$23.5M+6.7%	$22.02M0.0%
Payment, Tax Withholding, Share-Based Payment Arrangement	$8.82M-6.7%	$9.46M-1.0%	$9.56M-38.8%	$15.61M+3.2%
Payments to Acquire Businesses, Net of Cash Acquired	——	$97.4M—	——	$3.53M—
Payments to Acquire Productive Assets	$63.83M-56.6%	$147.18M+140%	$61.24M-1.0%	$61.87M+5.1%
Payments to Acquire Property, Plant, and Equipment	$62.8M+26.8%	$49.53M-12.9%	$56.85M-0.8%	$57.33M-2.3%
Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash	$5.1M-72.9%	$18.79M+103%	$9.27M—	——
Financing — other	——	——	$490K—	——
Dispositions of property, plant, and equipment	$4.57M+37.8%	$3.32M+418%	$640K-72.5%	$2.33M+158%
Cash received from option exercises	——	$56.52M-44.7%	$102.19M+127%	$44.97M+25.4%
Repayments of Long-term Lines of Credit	——	——	——	$306.8M—
Expected volatility	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Income Tax Benefit Recognized In Income	$9.71M-23.8%	$12.73M+31.1%	$9.71M+14.4%	$8.49M+7.2%
Granted (in shares)	$441.5K+38.8%	$318.02K+0.8%	$315.56K+0.9%	$312.6K-4.3%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value	——	——	——	——
Risk-free rate	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Intrinsic Value	$1.87M+46.1%	$1.28M-11.2%	$1.44M+23.4%	$1.17M-0.3%
Share Based Compensation Arrangement By Share Based Payment Award Expiration Year	2K0.0%	2K0.0%	2K0.0%	2K0.0%
Weighted-average dividend yield	——	——	——	——
Intrinsic value of stock options exercised	$18.2M-57.6%	$42.91M-21.5%	$54.68M+2.5%	$53.34M-14.0%
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	$57.01M-42.5%	$99.17M-25.7%	$133.43M+112%	$62.97M+20.8%
Stock Option Plan Expense	$32.67M+2.0%	$32.03M+6.5%	$30.08M+14.6%	$26.25M+16.7%
Stock Options Number Of Stock Incentive Plans	4—	——	40.0%	4+33.3%
Stockholders' Equity, Other	$1.17M+159%	-$1.98M-466%	$540K—	——
Average price paid (in dollars per share)	$2,070.40-11.7%	$2,344.84—	——	$1,942.64+3.0%
Number of shares purchased (in shares)	$932.5K+46.1%	$638.24K+380%	$132.97K-42.8%	$232.5K-80.6%
Treasury stock, value, acquired	$428.04M+19.3%	$358.74M+386%	$73.81M-35.3%	$114.07M-80.2%
Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions	$138K—	——	——	——
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions	——	$695K+164%	$263K-26.1%	$356K+6.9%
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations	$284K+37.2%	$207K-41.7%	$355K-15.9%	$422K+63.6%
Wages	$1.25B+7.7%	$1.16B+8.4%	$1.07B+7.8%	$996.1M—
EBIT	$338.25M-7.7%	$366.49M+7.6%	$340.57M-0.9%	$343.5M+0.1%
EBITDA	$403.09M-6.2%	$429.54M+7.0%	$401.43M-0.3%	$402.67M+0.1%
EBITDA	$403.09M-6.2%	$429.54M+7.0%	$401.43M-0.3%	$402.67M+0.1%
EBITDA margin	15.9%-1.7pp	17.7%-0.1pp	17.7%-1.1pp	18.9%+0.1pp
EBIT	$338.25M-7.7%	$366.49M+7.6%	$340.57M-0.9%	$343.5M+0.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Chemed.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Chemed's revenue?: Chemed (CHE) generated $2.5B in revenue over the trailing twelve months, up 2.1% year over year.
Is Chemed profitable?: Chemed reported $259.8M in net income over the trailing twelve months, a 10.2% net margin.
What are Chemed's profit margins?: Gross margin is 32.4% and operating margin is 12.9%, with a 10.2% net margin.
What is Chemed's earnings per share?: Chemed's diluted EPS over the trailing twelve months is $18.32.
Where does Chemed's income statement data come from?: Every line is extracted from Chemed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.